Key facts
- This page summarizes Deepak Jain's Form 4 filing for PROKIDNEY CORP. (PROK).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 13 Jul 2022, 21:32.
Deepak Jain - 11 Jul 2022 Form 4 Insider Report for PROKIDNEY CORP. (PROK)
- Reporting relationship
- Chief Operating Officer
- Issuer ticker
- PROK
- Reported as of
- 11 Jul 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Jul 2022, 21:32:03 UTC
- Next SEC filing
- 24 Oct 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Todd Girolamo as Attorney-in-Fact for Deepak Jain
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Deepak Jain filed Form 4 for PROKIDNEY CORP. (PROK) on 13 Jul 2022.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PROK
transaction
Derivative
Class B Ordinary Shares
Award
- Transaction value
- $0
- Shares
- +1,567,939
- Change %
- Price
- $0.000000
- Shares after
- 1,567,939
- Date
- 11 Jul 2022
- Ownership
- Direct
- Underlying class
- Class A Ordinary Shares
- Underlying amount
- 1,567,939
- Exercise price
- Footnotes
- F1, F2
PROK
transaction
Derivative
Common Units in ProKidney LP
Award
- Transaction value
- $0
- Shares
- +1,567,939
- Change %
- Price
- $0.000000
- Shares after
- 1,567,939
- Date
- 11 Jul 2022
- Ownership
- Direct
- Underlying class
- Class A Ordinary Shares
- Underlying amount
- 1,567,939
- Exercise price
- Footnotes
- F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
Each Class B Ordinary Share has no economic rights but entitles the reporting person to vote on all matters on which shareholders of the issuer vote and may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement (each as defined and as described in the issuer's Definitive Proxy Statement filed with the Securities and Exchange Commission on June 10, 2022), be exchanged, together with the paired Common Unit in ProKidney LP ("ProKidney") (a "Common Unit"), for a Class A Ordinary Share on a one-for-one basis.
Footnote F2
These 937,836 Class B Ordinary Shares and 630,103 Restricted Stock Rights in respect of Class B Ordinary Shares ("Class B PMEL RSRs") were received pursuant to the terms of the Business Combination Agreement by and between the issuer and ProKidney, dated as of January 18, 2022 (the "Business Combination Agreement") in exchange for historical interests held by the reporting person in ProKidney. The Class B PMEL RSRs vest in installments over a period through January 17, 2026, and upon vesting are immediately settled as Class B Ordinary Shares. The Class B Ordinary Shares and Class B PMEL RSRs do not expire.
Footnote F3
Each Common Unit may, at the election of the reporting person and subject to the limitations set forth in the Exchange Agreement and the Second Amended and Restated Company Partnership Agreement, be exchanged, together with the paired Class B Ordinary Share, into a Class A Ordinary Share on a one-for-one basis.
Footnote F4
These 937,836 Common Units and 630,103 Restricted Common Units of ProKidney Equity LLC that upon vesting will settle in Common Units ("PMEL RCUs") were received pursuant to the terms of the Business Combination Agreement in exchange for historical interests held by the reporting person in ProKidney. The PMEL RCUs vest in installments over a period through January 17, 2026. The Common Units and the PMEL RCUs do not expire.